[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-vessel-cerebrovascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-vessel-cerebrovascular-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,98,129,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100618286","targeting-neurovascular-coupling-in-cognitive-decline-via-nitrate-based-supplementation-100618286",false,"NCT07329647","Targeting Neurovascular Coupling in Cognitive Decline Via Nitrate-Based Supplementation","The Neurovascular Coupling as a Target for Cognitive Enhancement in Vascular Cognitive Decline Through an Innovative Nitrate-driven Dietary Supplementation.","DietNOBrain","Inclusion Criteria:\n\n* Formal diagnosis of cerebral small vessel disease (grades 1 to 3 in the Age-Related White Matter Changes Scale as assessed by Computerized Tomography or Magnetic Ressonance Imaging - MRI) and patients at high risk for cerebral small vessel disease with diabetes mellitus;\n* Subject has capacity and is capable of giving written informed consent;\n* Subject is able to read, comprehend and record information written in Portuguese.\n\nExclusion Criteria:\n\n* Vascular diseases other than cerebral Small Vessel Disease (cSVD);\n* Stroke event less than 6 months ago;\n* Unsuitable for MRI scanning because of presence of any standard MRI contraindication (e.g presence of a cardiac pacemaker, other medical implants or devices, or the presence of ferromagnetic metal foreign bodies);\n* Needle phobia;\n* Inability or intolerance to dietary polyphenol adjustment;\n* Current smoker;\n* Alcohol abuse, drug abuse or use of drugs affecting cognitive assessment, such as sedatives, hypnotics, nootropic drugs, cholinergic drugs;\n* Use of medications that may be contraindicated or interact with the high nitrate diet, such as nitroglycerin or nitrate preparations used for angina, or phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil (Viagral);\n* Patients previously diagnosed with dementia;\n* Presence of congenital mental retardation and severe neurological and psychiatric diseases;\n* Illiterate or severe visual or hearing impairment that may prevent patients from cooperating with cognitive assessment;\n* Relevant depression or other unrelated serious mental illness;\n* Severe cardiac, pulmonary, renal or hepatic insufficiency;\n* Patients who have participated in other interventional clinical studies within the last 3 months, or are participating in other interventional clinical studies.","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","Diet is established among the most relevant adjustable variables of human health in modern societies. The recognition by the World Health Organization of cognitive impairment and dementia associated with aging as one of the major public health challenges of our time, highlights the imperative need for a more comprehensive understanding of how different aspects of lifestyle, in particular diet, affect neural function and consequent cognitive performance throughout lifespan.\n\nThe brain is endowed with fine mechanisms for a precise spatial and temporal control of cerebral blood flow (CBF) according to neural activity, the neurovascular coupling (NVC). Mounting evidence from preclinical and human studies demonstrate that NVC dysfunction is a key early factor contributing to the pathogenesis of cognitive decline and vascular cognitive impairment (VCI) in aging and conditions associated with accelerated microvascular aging, such as cerebral small vessel disease (cSVD). Failure at any part of the NVC pathway disrupts CBF resulting in catastrophic depletion of oxygenation and energy supply to brain cells, and, in the long run, to neuronal dysfunction and cognitive impairment.\n\nThe investigators have shown that nitric oxide (NO) synthesized by neuronal nitric oxide synthase (nNOS) is a direct mediator of NVC and that decreased bioavailability of NO along aging compromised NVC and reduced local CBF. Shortly after the identification of nNOS as a source of NO for vasodilation in the brain, an alternative pathway for NO production independent of nNOS, relying on the sequential reduction of nitrate, the nitrate:nitrite:NO pathway, was unveiled.\n\nNitrate consumed in green leafy vegetables as part of a normal diet is bioactivated to nitrite and both compounds are permanent constituents of blood\u002Ftissues in animal species, influencing CBF and resulting in improvements in learning and memory in rodents and VCI patients. However, a critical question remains on whether NO produced from nitrite is functionally linked to neuronal activation. This is key to understanding whether dietary nitrate can be linked to neuronal-dependent CBF increases and cognitive performance.\n\nThe investigators and others have shown that upon excitatory stimulation, ascorbate is released from neurons being available for nitrite reduction and our preliminary data supports that NO bioavailability and CBF might be maintained independently of nNOS by the reduction of nitrite to NO in the brain extracellular space upon neuronal activation (unpublish data). This innovative mechanism functionally links the production of NO from nitrite to neuronal activation, triggering CBF increases and maintaining an operative NVC. A further facet is that, bridging diet and cognitive performance, this mechanism incorporates modulatory elements which is open to adjustment by diet via nitrate.\n\nThus, in this pilot trial a proof of concept study will be conducted to investigate the clinical impact of a dietary nitrate supplementation intervention in a clinical population with VCI due to small vessel disease, as measured by changes on NVC and cognitive performance.\n\nThe investigators hypothesise that functional NVC is maintained operative in VCI patients by increasing NO bioavailability in the extracellular space of the brain through a nitrate -rich diet that, in turn, supports an adequate CBF in response to neuronal activation, modulating the molecular mechanisms and cognitive performance of disease-related physiological and cognitive markers.",[27,28],"Small Vessel Cerebrovascular Disease","Diabete Mellitus","RECRUITING","2026-01-06",{"date":32,"type":33},"2026-01-09","ACTUAL",{"date":35,"type":33},"2025-05-09",{"date":37,"type":21},"2025-12-31",{"name":39,"class":40},"University of Coimbra","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100556506","telecoached-exercise-intervention-for-connectivity-enhancement-in-small-vessel-disease-teleconnect-svd-100556506","NCT06525987","Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD)","Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD): a Randomized Clinical Trial","TELECONNECT","Inclusion Criteria:\n\n* Age ≥60 years;\n* History of lacunar stroke occurred between 3 months and 10 years from screening and confirmed by neuroimaging or clinical data by an expert stroke physician;\n* Modified Rankin Scale (mRS) score of 0-1, indicating no symptoms or no significant disability;\n* A level of physical activity below recommended targets, i.e. \\\u003C150 minutes per week of moderate-to-vigorous exercise (24);\n* Ability to sign informed consent.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension;\n* Heart disease impairing the possibility of safely following an exercise protocol at the discretion of the treating physician;\n* Primary or secondary epilepsy;\n* Prostheses, implants, and any device that might impair the performance of either high-density electroencephalogram or the exercise intervention;\n* Cognitive impairment (Mini Mental State Examination score ≤26 at follow-up);\n* Lack of access to Internet-based facilities or poor technological alphabetization impairing the adherence to the trial protocol;\n* Any major physical or psychiatric comorbidity that in the judgement of the treating physician might compromise the ability to undergo an exercise intervention.","60 Years",{"count":52,"type":21},60,[24],"The TELECONNECT-SVD study is a prospective, randomized, multicenter trial aimed at testing the efficacy of a remotely delivered exercise protocol on brain functional connectivity in patients with small vessel disease (SVD)-related ischemic stroke. The study will recruit patients aged ≥60 with a history of lacunar stroke, minimal disability (modified Rankin Scale score 0-1), and low physical activity levels.\n\nThe trial will include 60 participants randomized 1:1 to either a 24-week telecoached exercise intervention or usual care. The exercise program consists of multicomponent physical exercises delivered remotely twice a week. Assessments will be conducted at baseline, 12 weeks, 24 weeks, and 48 weeks.\n\nPrimary outcomes include changes in brain functional connectivity assessed by high-density EEG and improvements in physical fitness measured by the Senior Fitness Test. Secondary outcomes encompass changes in physical activity levels, anthropometric measurements, and vital signs.\n\nThe study employs a \"wait list\" design, where the control group receives the intervention after the initial 24-week period. This approach allows for assessment of the intervention's immediate effects and the retention of benefits after cessation.\n\nKey features of the protocol include:\n\n* Use of telecoaching to enhance adherence to the exercise program\n* Comprehensive assessment of brain connectivity using advanced EEG analysis techniques\n* Focus on patients with SVD, who may benefit significantly from exercise interventions\n* Evaluation of both neurophysiological and clinical outcomes\n\nThe study aims to provide evidence for the potential benefits of exercise in enhancing brain connectivity and physical fitness in SVD patients, potentially informing future treatment guidelines and preventive strategies for this population.",[56,27],"Lacunar Stroke","2025-11-24",{"date":59,"type":33},"2025-12-02",{"date":61,"type":33},"2025-05-02",{"date":63,"type":21},"2026-12-31",{"name":65,"class":40},"University of L'Aquila",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100565981","optimal-target-low-density-lipoprotein-cholesterol-level-for-small-vessel-occlusion-stroke-100565981","NCT06649240","Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke","Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)","SVO70","Inclusion Criteria:\n\n1. Age 19 years or older\n2. Patients with objectively confirmed small vessel occlusive infarctions in the subcortical or brainstem regions, identified through neuroimaging (MRI or CT)\n3. Patients with a history of symptomatic ischemic stroke caused by the lesion described in 2), occurring within 180 days prior to enrollment\n4. Patients or guardians who agree to the study protocol and sign with informed consent\n\nExclusion Criteria:\n\n1. Patients requiring intensive LDL cholesterol management (LDL-C \\\u003C70 mg\u002FdL) due to another condition, with LDL cholesterol targets specified in the guidelines for that condition\n2. Patients contraindicated for statin use (e.g., active liver disease, serum transaminase levels elevated more than three times the normal limit, muscle disorders, hypersensitivity to statins, or taking medications contraindicated for use with statins)\n3. Women who are pregnant, breastfeeding, or intending to become pregnant during the study period\n4. Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion","19 Years",{"count":77,"type":21},4016,[24],"Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke guidelines remain deficient in providing optimal target low-density lipoprotein (LDL)-cholesterol levels tailored to the stroke subtypes. Most clinical trials on LDL-cholesterol management have not differentiated between stroke subtypes or have primarily focused on large artery atherosclerosis (LAA) stroke, leaving a gap in evidence for managing LDL-cholesterol in other stroke subtypes, e.g., small vessel occlusion (SVO) stroke. While hypertension is the leading risk factor for SVO strokes, the link between elevated LDL-cholesterol and SVO stroke is also recognized. Establishing optimal LDL-cholesterol targets for SVO stroke would significantly enhance secondary prevention strategies and improve patient outcome. Thus, the investigators aim to compare intensive versus standard lipid-lowering in patients with SVO stroke. SVO70 is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult participants with objectively confirmed SVO stroke within 180 days of randomization will be included. Exclusion criteria include those with predefined LDL-cholesterol targets for other conditions, statin contraindications, or women who are pregnant, breastfeeding, or planning pregnancy during the study period. Eligible participants will be randomized 1:1 to target LDL-cholesterol \\\u003C70 mg\u002FdL (intensive group) or 90-110 mg\u002FdL (standard group). The trial plans to enroll 4,016 participants, with the primary outcome being major adverse cardiovascular events-cardiovascular death, stroke, and acute coronary syndrome-during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal LDL-cholesterol target for patients with SVO stroke.",[81,27,82,83,84],"Ischemic Stroke","Cholesterol, LDL","Secondary Prevention","Cardiovascular Diseases",[86,81,83,82,87],"Cerebral Small Vessel Diseases","Statins","2025-05-17",{"date":90,"type":33},"2025-05-21",{"date":92,"type":33},"2024-10-04",{"date":94,"type":21},"2030-09",{"name":96,"class":40},"Seoul National University Hospital",46,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":109,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":66},"100571035","antiplatelet-therapy-and-endothelial-stabilizing-agents-in-cerebral-small-vessel-diseases-100571035","NCT06715007","Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases","Athena-cSVD","Inclusion criteria:\n\n1. Age ≥ 30 years and ≤ 79 years.\n2. A recent small subcortical infarct that occurred within 3 weeks prior to randomization; or patient with whiter matter hyperintensities with a 2-3 grading on Fazekas scale.\n3. Absence of signs or symptoms of cortical dysfunction, such as aphasia, apraxia, agnosia, agraphia, homonymous visual field defect.\n4. Modified Rankin score of ≤ 4.\n5. In the absence of any other pathology in the parent artery at the site of the origin of the penetrating artery (focal atheroma, parent vessel dissection, vasculitis, vasospasm, and so on).\n\n7\\. No ipsilateral cervical carotid stenosis (≥30%) by brain high resolution magnetic resonance imaging (HRMRI) or computed tomography angioplasty (CTA) or (magnetic resonance angioplasty) MRA and cervical artery ultrasound, if qualifying event is hemispheric. No vertebra artery stenosis (≥30%) by brain HRMRI or CTA or MRA and cervical artery ultrasound, if the lesion is in the territory of posterior circulation.\n\n8\\. No major-risk cardioembolic sources requiring anticoagulation or other specific therapy.\n\n9\\. Patient agrees with follow-up visits and is available by phone. 10. Patient understands the purpose and requirements of the study, can make him\u002Fherself understood, and has signed informed consent.\n\nExclusion criteria:\n\n1. Intracranial aneurysms that need surgical treatment. Other significant active neurological illness e.g seizures, multiple sclerosis, intracranial tumor (except meningioma) or any intracranial vascular malformation.\n2. Active cardiac disease (atrial fibrillation, myocardial infarct in last six months, active angina, symptomatic cardiac failure).\n3. History of any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural).\n4. Known allergy or contraindication to aspirin, clopidogrel, cilostazol, isosorbide mononitrate or statin.\n5. Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets \\\u003C 100,000, hematocrit \\\u003C 30, international normalized ratio (INR) \\> 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure \\> 180 mm Hg or diastolic pressure \\> 115 mm Hg), severe liver impairment (aspartate transaminase \\[AST\\] or alanine transaminase \\[ALT\\] \\> 3 x normal, cirrhosis), creatine kinase \\> 5 times the upper limit of normal (ULN) at final screening, severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \\\u003C 20mL\u002Fmin\u002F1.73 square meter at final screening.\n6. Major surgery (including open femoral, aortic, cardiac or carotid surgery) within previous 30 days or planned in the 1 year after enrollment.\n7. Dementia or psychiatric problem that prevents the patient from relevant evaluation or follow-up reliably.\n8. Co-morbid conditions that may limit survival to less than 1 year.\n9. Currently breastfeeding, pregnancy, planning to become pregnant and unwilling to use contraception for the duration of this study\n10. Unable to tolerate, or contraindication to, MRI.\n11. Enrollment in another study that would conflict with the current study.","30 Years","79 Years",{"count":108,"type":21},300,"6 Months","OBSERVATIONAL","Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).",[113,27,114],"Stroke, Ischemic","White Matter Hyperintensity",[116,114,117,118,119],"cerebral small vessel disease","recent small subcortical infarcts","Endothelial dysfunction","cilostazol","2025-03-25",{"date":122,"type":33},"2025-03-28",{"date":124,"type":33},"2024-12-20",{"date":126,"type":21},"2026-01-20",{"name":128,"class":40},"The First Affiliated Hospital with Nanjing Medical University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":140,"conditions":141,"keywords":147,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":66},"100507277","the-imperial-comprehensive-cognitive-assessment-in-cerebrovascular-disease-ic3-100507277","NCT05885295","The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)","Understanding Factors Affecting Cognitive Function in Cerebrovascular Disease","IC3","Inclusion Criteria:\n\n* Aged \\> 18\n* Evidence of confirmed stroke (for patients)\n* Ability to concentrate for 15 minutes at a time to engage with cognitive testing\n\nExclusion Criteria for the main study:\n\n* Pre-stroke diagnosis of dementia\n* Severe visuo-spatial problems, fatigue, or mental health problems\n* Severe hearing impairment in the presence of reading comprehension impairment\n\nExclusion Criteria for the MRI imaging sub-study:\n\n* Pregnancy\n* Presence of metal implants\n* Claustrophobia",true,{"count":139,"type":21},700,"Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors. These deficits negatively impact recovery and therapy engagement, and their treatment is consistently rated as high priority by stakeholders and clinicians. Although clinical guidelines endorse cognitive screening for post-stroke management, there is currently no gold standard approach for identifying cognitive deficits after stroke, and clinical stroke services lack the capacity for long-term cognitive monitoring and care. Currently available assessment tools are either not stroke-specific, not in-depth or lack scalability, leading to heterogeneity in patient assessments. To address these challenges, a cost-effective, scalable, and comprehensive screening tool is needed to provide a stroke-specific assessment of cognition. The current study presents such a novel digital tool, the Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3), designed to detect both domain-general and domain-specific cognitive deficits in patients after stroke with minimal input from a health professional. To ensure its reliability, we will utilise multiple validation approaches, and aim to recruit a large normative sample of age-, gender-, and education-matched UK-based controls. Moreover, the IC3 assessment will be integrated within a larger prospective observational longitudinal clinical trial, where post-stroke cognition will be examined in tandem with brain imaging and blood biomarkers to identify novel multimodal biomarkers of recovery after stroke. By leveraging this rich dataset, our study will allow more precise targeting of cognitive rehabilitation to stroke survivors that are most at risk of progressive cognitive decline and have the greatest potential for recovery.",[142,143,144,145,27,146],"Stroke","Stroke (CVA) or TIA","Dementia, Vascular","Cerebrovascular Disorders","Cognitive Impairment",[148,149,150,151,152,153,154,155,156,157,158,159,160,161,162],"dementia","MRI","blood biomarkers","neurofilament light","amyloid","tau","GFAP","white matter hyper intensity","micro bleed","small vessel disease","cognitive impairment","vascular dementia","stroke","aphasia","neglect","2023-05-30",{"date":165,"type":33},"2023-06-01",{"date":167,"type":33},"2021-12-01",{"date":169,"type":21},"2028-05-15",{"name":171,"class":40},"Imperial College London",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":180,"maxAge":4,"enrollmentInfo":181,"targetDuration":183,"studyType":110,"phases":4,"briefSummary":184,"conditions":185,"keywords":189,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":66},"100495682","prognosis-of-cerebral-small-vessel-disease-100495682","NCT05734378","Prognosis of Cerebral Small Vessel Disease","Prognosis of Cerebral Small Vessel Disease - a Prospective Cohort Study (PRO-SVD)","PRO-SVD","Inclusion Criteria:\n\n* Hypertensive deep perforator arteriolopathy (DPA), clinically symptomatic with either ICH, ischaemic stroke, cognitive impairment or severe radiological manifestation (Fazekas ≥II)\n* Cerebral amyloid angiopathy (CAA according to modified Boston or Edinburgh criteria), clinically symptomatic with either ICH (including cSAH), amyloid spells, cognitive impairment or severe radiological manifestation (CMB≥2)\n* Other SVD (i.e. CADASIL or other sporadic or genetic SVD)\n\nExclusion Criteria:\n\n* Life expectancy of \\\u003C6 months due to not-SVD related causes (i.e. cancer)\n* Patient is unlikely to attend follow-up visits","16 Years",{"count":182,"type":21},900,"1 Year","Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation.\n\nThe aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients with SVD according to the type of index presentation.",[186,27,187,188],"Cerebral Amyloid Angiopathy","Cadasil","CAA - Cerebral Amyloid Angiopathy",[157,190,191,192,193,194],"CAA","cerebral amyloid angiopathy","hypertensive arteriopathy","deep perforator arteriopathy","CADASIL","2023-03-06",{"date":197,"type":33},"2023-03-08",{"date":199,"type":33},"2020-12-01",{"date":201,"type":21},"2030-11-30",{"name":203,"class":40},"Insel Gruppe AG, University Hospital Bern"]